Language

English

Publication Date

12-16-2024

Journal

The Journal of Infectious Diseases

DOI

10.1093/infdis/jiae311

PMID

38864524

Abstract

Background: The in vitro cultivation of human noroviruses allows a comparison of antibody levels measured in neutralization and histo-blood group antigen (HBGA)-blocking assays.

Methods: Serum samples collected during the evaluation of an investigational norovirus vaccine (HIL-214 [formerly TAK-214]) were assayed for neutralizing antibody levels against the vaccine's prototype Norwalk virus/genogroup I, genotype 1 (GI.1) (P1) virus strain. Results were compared with those previously determined using HBGA-blocking assays.

Results: Neutralizing antibody seroresponses were observed in 83% of 24 vaccinated adults, and antibody levels were highly correlated (r = 0.81; P < .001) with those measured by HBGA blocking.

Conclusions: Genogroup I, genotype 1 (GI.1)-specific HBGA-blocking antibodies are a surrogate for neutralization of GI.1 norovirus.

Keywords

Adult, Female, Humans, Male, Middle Aged, Young Adult, Antibodies, Blocking, Antibodies, Neutralizing, Antibodies, Viral, Blood Group Antigens, Caliciviridae Infections, Genotype, Neutralization Tests, Norovirus, Norwalk virus, Viral Vaccines, antibody, histo-blood group antigen, human norovirus, neutralization, vaccine

Comments

Clinical Trials Registration. Clinicaltrials.gov NCT02475278.

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.